Seagen - SGEN Stock Forecast, Price & News

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SGEN shares.
View SGEN analyst ratings or view top-rated stocks.

16 equities research analysts have issued 12-month price targets for Seagen's stock. Their SGEN share price forecasts range from $135.00 to $188.00. On average, they anticipate the company's share price to reach $161.21 in the next year. This suggests a possible upside of 16.8% from the stock's current price.
View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts.

Seagen's stock was trading at $128.51 at the start of the year. Since then, SGEN stock has increased by 7.4% and is now trading at $138.00.
View the best growth stocks for 2023 here.

Seagen saw a increase in short interest in January. As of January 15th, there was short interest totaling 3,000,000 shares, an increase of 15.4% from the December 31st total of 2,600,000 shares. Based on an average daily volume of 982,200 shares, the short-interest ratio is currently 3.1 days.
View Seagen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our SGEN earnings forecast.

Seagen will be holding an earnings conference call on Wednesday, February 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Seagen Inc. (NASDAQ:SGEN) issued its quarterly earnings results on Thursday, October, 28th. The biotechnology company reported ($1.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $1.05. The biotechnology company earned $424.60 million during the quarter, compared to analysts' expectations of $384.83 million. Seagen had a negative net margin of 34.16% and a negative trailing twelve-month return on equity of 21.56%. The business's quarterly revenue was down 60.0% on a year-over-year basis. During the same period last year, the company earned $3.50 EPS.

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Seagen's stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.24%), Manning & Napier Group LLC (0.19%), Pinnacle Associates Ltd. (0.13%), Pinnacle Associates Ltd. (0.13%), National Bank of Canada FI (0.10%) and DekaBank Deutsche Girozentrale (0.09%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends.

Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGEN stock can currently be purchased for approximately $138.00.

Seagen (NASDAQ:SGEN) has a market capitalization of $25.62 billion and generates $1.57 billion in revenue each year. The biotechnology company earns $-674,470,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis.

The company employs 2,675 workers across the globe.

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001.